97 related articles for article (PubMed ID: 7903196)
1. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients.
Pupa SM; Ménard S; Andreola S; Colnaghi MI
Cancer Res; 1993 Dec; 53(24):5864-6. PubMed ID: 7903196
[TBL] [Abstract][Full Text] [Related]
2. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage.
Pupa SM; Ménard S; Morelli D; Pozzi B; De Palo G; Colnaghi MI
Oncogene; 1993 Nov; 8(11):2917-23. PubMed ID: 8105438
[TBL] [Abstract][Full Text] [Related]
3. Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas.
Bodey B; Bodey B; Gröger AM; Luck JV; Siegel SE; Taylor CR; Kaiser HE
Anticancer Res; 1997; 17(2B):1319-30. PubMed ID: 9137492
[TBL] [Abstract][Full Text] [Related]
4. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
[TBL] [Abstract][Full Text] [Related]
5. [Expression of the c-erbB-2 oncoprotein in mammary Paget's disease. Immunohistochemical study by using 3 antibodies].
Edorh A; Parache RM; Migeon C; N'Sossani B; Rihn B
Pathol Biol (Paris); 1995 Sep; 43(7):584-9. PubMed ID: 8570262
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumour suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast.
Sharma BK; Ray A; Kaur S; Gupta S
Indian J Exp Biol; 1999 Mar; 37(3):223-7. PubMed ID: 10641149
[TBL] [Abstract][Full Text] [Related]
7. Detection of c-erbB-2 oncoprotein expression in breast tissue by multiparameter flow cytometry.
Li BD; Bauer KD; Carney WP; Duda RB
J Surg Res; 1993 Mar; 54(3):179-88. PubMed ID: 7682635
[TBL] [Abstract][Full Text] [Related]
8. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells.
Shawver LK; Mann E; Elliger SS; Dugger TC; Arteaga CL
Cancer Res; 1994 Mar; 54(5):1367-73. PubMed ID: 7907001
[TBL] [Abstract][Full Text] [Related]
9. C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast relates to high histological grade and loss of oestrogen receptor protein.
Looi LM; Cheah PL
Malays J Pathol; 1998 Jun; 20(1):19-23. PubMed ID: 10879259
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.
Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ
Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782
[TBL] [Abstract][Full Text] [Related]
11. Reduced expression of c-erbB2 gene product in human mammary carcinoma SK-BR-3 cells treated with interferon-gamma and tumor necrosis factor-alpha.
Kumar R; Mendelsohn J
Anticancer Res; 1994; 14(3A):1001-8. PubMed ID: 7915505
[TBL] [Abstract][Full Text] [Related]
12. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
Arteaga CL; Winnier AR; Poirier MC; Lopez-Larraza DM; Shawver LK; Hurd SD; Stewart SJ
Cancer Res; 1994 Jul; 54(14):3758-65. PubMed ID: 7913407
[TBL] [Abstract][Full Text] [Related]
13. Relationship between c-erbB-2 oncoprotein, epidermal growth factor receptor, and estrogen receptor expression in patients with ductal breast carcinoma. Association with tumor phenotypes.
Harłoziñska A; Bar JK; Wenderski R; Bebenek M
In Vivo; 1996; 10(2):217-22. PubMed ID: 8744803
[TBL] [Abstract][Full Text] [Related]
14. Generation of monoclonal antibody CIBCgp185 against C-erbB-2 oncoprotein and its clinical evaluation.
Meenakshi A; Kumar RS; Kumar NS
Hum Antibodies; 2001; 10(3-4):101-7. PubMed ID: 11847421
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation.
Giani C; Casalini P; Pupa SM; De Vecchi R; Ardini E; Colnaghi MI; Giordano A; Ménard S
Oncogene; 1998 Jul; 17(4):425-32. PubMed ID: 9696035
[TBL] [Abstract][Full Text] [Related]
16. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
Ethier SP; Kokeny KE; Ridings JW; Dilts CA
Cancer Res; 1996 Feb; 56(4):899-907. PubMed ID: 8631031
[TBL] [Abstract][Full Text] [Related]
17. Correlation between histological grade and c-erbB2 oncoprotein overexpression in infiltrating ductal carcinoma of breast.
Looi LM; Cheah PL; Yap SF
Malays J Pathol; 1997 Jun; 19(1):35-9. PubMed ID: 10879240
[TBL] [Abstract][Full Text] [Related]
18. Distribution of prognostically unfavourable product of c-erbB-2 oncogene and EGF-R in carcinomas of the breast and uterine cervix.
Ray A; Naik SL; Sharma BK
Indian J Physiol Pharmacol; 2002 Oct; 46(4):423-33. PubMed ID: 12683217
[TBL] [Abstract][Full Text] [Related]
19. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
[TBL] [Abstract][Full Text] [Related]
20. Correlations of morphology, proliferation indices, and oncogene activation in ductal breast carcinoma: nuclear grade, S-phase, proliferating cell nuclear antigen, p53, epidermal growth factor receptor, and c-erb-B-2.
Dabbs DJ
Mod Pathol; 1995 Aug; 8(6):637-42. PubMed ID: 8532697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
